Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNA02-48 Injection in Chinese Adult Participants
NCT06939777Phase 2Completed
- Sponsor
- Sinovac Life Sciences
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SNA02-48 in Tetanus (12 arms), sponsored by Sinovac Life Sciences. Primary endpoints: Incidence of adverse reactions at 105 days and Increase in serum tetanus antibody levels from baseline at 12 hours post-administration. Started Apr 2025; status: completed.
02
Drugs
SNA02-48
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06939777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06939777.